Nortons Inc. is representing Aspen Pharmaceuticals (“Aspen”) and GlaxoSmithKline in relation to Aspen acquiring a portfolio of products from GlaxoSmithKline, in so far as they are sold to the “rest of the world”, excluding North America and Europe. The portfolio of products include Solpadeine, Phillips MOM, Zantac, Nytol, Cartia, Valad, Beconase, Dequadin, Borstol, Cofal, Hedex, Kwell, Cafenol, Valoid, Aspirin concept, Cortal, Brooklax, Cofta, Lipeze, Alphosyl, Quellada, Paramed, Specific Pain Remedy, Calsuba, Glucolin, Cytexin, Decavit Plus and Ashton & Parsons (“the Prism products”). Upon completion of the proposed transaction, Aspen will acquire sole control over the Prism products. Nortons Inc. is assisting the merging parties with notifying the proposed transaction in a number of African jurisdictions, including South Africa, Namibia, Swaziland, Kenya and Tanzania. The transaction has also been notified in Brazil.